Heidi M Kieler-Ferguson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1017705/publications.pdf

Version: 2024-02-01

23 papers 563

687220 13 h-index 642610 23 g-index

23 all docs 23 docs citations

times ranked

23

1124 citing authors

#	Article	IF	CITATIONS
1	Design, Synthesis, and Biological Evaluation of a Robust, Biodegradable Dendrimer. Bioconjugate Chemistry, 2010, 21, 764-773.	1.8	95
2	Inhibition of RORÎ ³ T Skews TCRα Gene Rearrangement and Limits T Cell Repertoire Diversity. Cell Reports, 2016, 17, 3206-3218.	2.9	51
3	Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan. Journal of Controlled Release, 2011, 153, 288-296.	4.8	50
4	Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1548-1554.	1.3	44
5	Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 130-138.	3.3	41
6	Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. ACS Medicinal Chemistry Letters, 2019, 10, 1530-1536.	1.3	38
7	Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids. European Journal of Pharmaceutical Sciences, 2017, 103, 85-93.	1.9	33
8	Chemotherapeutic Evaluation of a Synthetic Tubulysin Analogue–Dendrimer Conjugate in C26 Tumor Bearing Mice. ChemMedChem, 2011, 6, 49-53.	1.6	31
9	Combination of EP ₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncolmmunology, 2021, 10, 1896643.	2.1	28
10	The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in <i>Nod2</i> knockout mice. Innate Immunity, 2019, 25, 132-143.	1.1	27
11	Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2721-2726.	1.0	18
12	Discovery of $\langle i \rangle N \langle i \rangle$ -(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases. ACS Medicinal Chemistry Letters, 2020, 11, 114-119.	1.3	18
13	Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors. SLAS Discovery, 2021, 26, 88-99.	1.4	15
14	Carbamate and <i>N</i> -Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 389-396.	1.3	14
15	Hierarchical Particle Approach for Co-Precipitated Amorphous Solid Dispersions for Use in Preclinical In Vivo Studies. Pharmaceutics, 2021, 13, 1034.	2.0	12
16	A robust and quantitative method for tracking liposome contents after intravenous administration. Journal of Controlled Release, 2014, 176, 86-93.	4.8	11
17	Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing. Journal of Medicinal Chemistry, 2022, 65, 6001-6016.	2.9	8
18	Discovery of IDO1 inhibitors containing a decahydroquinoline, decahydro-1,6-naphthyridine, or octahydro-1H-pyrrolo[3,2-c]pyridine scaffold. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128314.	1.0	7

#	Article	IF	CITATIONS
19	STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors. Molecular Cancer Therapeutics, 2022, 21, 282-293.	1.9	6
20	Resolution of enantiomers of a series of chiral alkoxy-modified phthalocyaninato nickel(ii) complexes by enantioselective HPLC. Dalton Transactions, 2011, 40, 11809.	1.6	5
21	Flexibility in Drug Product Development: A Perspective. Molecular Pharmaceutics, 2021, 18, 2455-2469.	2.3	4
22	SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128214.	1.0	4
23	Sonoporationâ€Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression. Advanced Therapeutics, 2021, 4, 2100154.	1.6	3